RT Journal Article
SR Electronic
T1 Non-pharmaceutical behavioural measures for droplet-borne biological hazards prevention: Health-EDRM for COVID-19 (SARS-CoV-2) Pandemic
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.29.20116475
DO 10.1101/2020.05.29.20116475
A1 Chan, Emily Ying Yang
A1 Shahzada, Tayyab Salim
A1 Sham, Tiffany Sze Tung
A1 Dubois, Caroline
A1 Huang, Zhe
A1 Liu, Sida
A1 Ying-en Ho, Janice
A1 KC Hung, Kevin
A1 On, Kwok Kin
A1 Kayano, Ryoma
A1 Shaw, Rajib
YR 2020
UL http://medrxiv.org/content/early/2020/05/29/2020.05.29.20116475.abstract
AB Introduction Non-pharmaceutical interventions to facilitate response to the COVID-19 pandemic, a disease caused by novel coronavirus SARS-CoV-2, are urgently needed. Using the WHO health emergency and disaster risk management (health-EDRM) framework, behavioural measures for droplet-borne communicable disease, with their enabling and limiting factors at various implementation levels were evaluated.Sources of data Keyword search was conducted in PubMed, Google Scholar, Embase, Medline, Science Direct, WHO and CDC online publication database. Using OCEBM as review criteria, 105 English-language articles, with ten bottom-up, non-pharmaceutical prevention measures, published between January 2000 and May 2020 were identified and examined.Areas of Agreement Evidence-guided behavioural measures against COVID-19 transmission for global at-risk communities are identified.Area of Concern Strong evidence-based systematic behavioural studies for COVID-19 prevention are lacking.Growing points Very limited research publications are available for non-pharmaceutical interventions to facilitate pandemic response.Areas timely for research Research with strong implementation feasibility that targets resource-poor settings with low baseline Health-EDRM capacity is urgently need.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere is no external funding for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval is exempted as no new data were collected or used in this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData sharing is not applicable to this article as no new data were created or analyzed in this study.